FDA: approval of zolgensma was based on manipulated data

The maker of Zolgensma (onasemnogene abeparvovec-xioi) gave manipulated data to the U.S. Food and Drug Administration when it approved the drug, the agency said Tuesday.

In late May, the FDA approved the gene therapy Zolgensma to treat children with a severe form of spinal muscular atrophy, a leading genetic cause of infant death. The drug costs $2.125 million for a one-time treatment, CBS News reported. A month after the approval, the FDA discovered a “data manipulation issue that impacts the accuracy of certain data from product testing performed in animals,” according to the agency.

The FDA said the drug’s maker AveXis, a unit of Novartis, knew about the data problem before the drug was approved but did not inform the FDA until after the drug was given the green light, CBS News reported. “The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties,” according to Peter Marks, an FDA official. Despite the inaccurate data, the FDA said it “remains confident that Zolgensma should remain on the market.”

Source: Read Full Article

Related posts:
  1. Study examines effects of different opioids on driving performance
  2. Scientists: “On the basis of the walking speed really possible to predict mortality”
  3. Hospital staff find themselves on the front lines of war on human trafficking
  4. Expectant mothers can mitigate the impact of marijuana on baby’s brain development
  5. Many post on social media under the influence of drugs—and regret it